The US Food and Drug Administration has cleared the BD OneFlow LST Test and the BD OneFlow B-CLPD T1 Test for clinical use in identifying and diagnosing B-cell non-Hodgkin lymphoma, including chronic lymphocytic leukemia, according to Waters Corporation, the manufacturer.
In validation testing, the assays showed 96.3% sensitivity and 98.2% specificity for identifying CLL. Designed as a ready-to-use system that replaces manual liquid reagent cocktails, the workflow combines reagents, staining protocols, and assay templates to cut manual preparation steps by 95%, according to a press release by Waters.
The manufacturer said the tests were built on research from the EuroFlow Consortium and the assays are the first in the BD OneFlow portfolio to receive FDA clearance, with US commercial availability scheduled for spring 2027.

Leave feedback about this